Tofactitinib in PsA & RA: Nine Year Safety Data A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified. https://t.co/nVglUz6FJC https://t.co/t3dI5SzjJa

Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/4EH6rBS0sJ https://t.co/B1uceAPGTB

Voclosporin in SLE - Long-Term Safety and Efficacy The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study. https://t.co/uiqi8J9rrP https://t.co/3r6aAI3WTj

"Ask Cush Anything" Returns Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything” https://t.co/bjMuMPlCHK https://t.co/rmAwOsNSvq

Study of 48 Jo-1+ anti synthetase pts shows Ab levels signif correlated w/ activity (r=0.4, p=.03) & CK (r=0.34, p=.002) & were signif higher w/ active disease (91.7 vs 44.4 IU/L). https://t.co/5TJYatLsEk Modest correl. prev seen https://t.co/tIsLCODKB6 https://t.co/rWA6M50ufV

Infectious Risk with B Cell Therapies in Lupus A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy. https://t.co/Dko5UQAl0G https://t.co/DQcrWtzQuY

JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis". Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/fGgTLWj8Hc https://t.co/65hpkI8oo0

Danger with Hydroxychloroquine Nonadherence in SLE A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality. https://t.co/1trDJoTypb https://t.co/c7oPyxF8mC

SLE and Pregnancy Outcomes Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease. https://t.co/ojFccY6kTT https://t.co/kJpIZP1kSd

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. https://t.co/OxcpnJ5EOe https://t.co/ggOnwt3wck

Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/hkDuCOYICy https://t.co/ZGicUqXN8l